DOI: 10.21088/ijnns.0975.0223.17225.8

International Journal of Neurology and Neurosurgery
Volume 17, Number 2 May-August 2025

Review Article

Role of Metabolites in Neurological Diseases

Sayak Sanyal[1], Shrijal Singh[2], Prachi Srivastava[3]

How to cite this article:

Sayak Sanyal, Shrijal Singh, Prachi Srivastava. Role of Metabolites in Neurological Diseases. International Journal of Neurology and Neurosurgery. 2025; 17(2): 124-135.

ABSTRACT

Metabolites, as essential biochemical molecules, play a critical role in brain metabolism and neurological health. They contribute to energy production, neurotransmitter synthesis, and cellular signaling, making them integral to normal brain function. Dysregulation of metabolites is a hallmark of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Impairments in glucose metabolism, oxidative stress, and neurotransmitter imbalances significantly impact neuronal function and disease progression. Emerging research in metabolomics has enabled the identification of disease specific biomarkers, providing insights into early diagnosis and potential therapeutic interventions. Additionally, the gut brain axis has been recognized as a key regulator of neurochemical processes, further emphasizing the systemic nature of metabolic influences on neurological health. Advances in metabolite based therapeutics, such as targeted metabolic modulation and antioxidant strategies, offer promising avenues for treating neurodegenerative and psychiatric disorders. Despite the complexity of metabolomic data, integrating multi-omics approaches and artificial intelligence driven analytics holds great potential for personalized medicine in neurology. This review explores the role of metabolites in brain function, their involvement in neurological diseases, and the future directions of metabolomics in clinical applications.

KEYWORDS

• Alzheimer's • Gut-brain axis • Metabolites • Neurological disease • Parkinson's

Author's Affiliation:

[1]Student, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

[2]Student, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

[3]Associate Professor, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

Corresponding Author:

Prachi Srivastava, Associate Professor, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

E-mail: psrivastava@amity.edu

➢ **Received:** 13-03-2025 ➢ **Accepted:** 02-05-2025

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (https://www.rfppl.co.in)

INTRODUCTION

Metabolites are small molecules that play a pivotal role in the biochemical processes essential for human survival. They are the intermediates or end products of metabolism, which includes all the chemical reactions occurring in the body to convert food into energy and synthesize necessary compounds. These molecules are broadly classified into two categories: primary and secondary metabolites. Primary metabolites, such as glucose, amino acids, and nucleotides, are directly involved in fundamental physiological processes like energy production, protein synthesis, and genetic material formation.[1] Secondary metabolites, on the other hand, are not essential for basic survival but contribute to specialized functions, such as hormone regulation and defense mechanisms.[2]

Metabolites serve various critical roles in the body. They are central to energy production, as molecules like glucose and fatty acids undergo pathways such as glycolysis, the citric acid cycle, and beta-oxidation to generate ATP, the energy currency of cells.[3] Additionally, metabolites like amino acids and nucleotides act as building blocks for proteins and nucleic acids, respectively. Some metabolites also function as regulators by serving as cofactors for enzymatic reactions or as signaling molecules to modulate physiological processes.[2] Furthermore, they are vital in detoxification, aiding the liver and kidneys in breaking down and excreting toxins and metabolic waste products.[1] The study of metabolites, known as metabolomics, provides valuable insights into the body's metabolic state and is a growing field in systems biology. It helps identify biomarkers for diseases, understand the impact of diet and drugs, and develop personalized medical approaches.[4] By studying the complex network of metabolites, researchers can gain a deeper understanding of human health and disease mechanisms, paving the way for innovative diagnostic and therapeutic strategies.[3]

Metabolites play a significant role in the functioning of the nervous system and are crucial in understanding the pathophysiology of neurological diseases. The brain, which has a high metabolic demand, relies on specific metabolites to maintain its complex functions, including energy production, neurotransmitter synthesis, and cellular signaling. Disruptions in metabolite levels or metabolic pathways can contribute to the development and progression of various neurological disorders. For instance, glucose, the primary energy source for the brain, undergoes glycolysis and oxidative phosphorylation to meet the energy requirements of neuronal activity. Impairments in glucose metabolism have been linked to neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.[5]

Altered levels of neurotransmitter related metabolites are another key factor in neurological diseases. For example, gamma aminobutyric acid (GABA) and glutamate, which are involved in inhibitory and excitatory neurotransmission, respectively, play critical roles in maintaining neuronal balance. Dysregulation of these metabolites is associated with disorders like epilepsy, schizophrenia, and major depressive disorder[6] Additionally, oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) and antioxidants, can lead to the accumulation of harmful metabolites, causing neuronal damage and contributing to conditions such as multiple sclerosis and amyotrophic lateral sclerosis.[7]

The emerging field of metabolomics has provided significant insights into the metabolic alterations associated with neurological diseases. By analyzing cerebrospinal fluid, blood, or brain tissue samples, researchers can identify disease specific biomarkers that aid in early diagnosis and monitoring. For example, reduced levels of N-acetylaspartate, a metabolite involved in neuronal health, have been identified in patients with Alzheimer's disease and other neurodegenerative disorders.[8] Furthermore, metabolomic studies have shed light on the role of the gut-brain axis, where metabolites produced by gut microbiota influence brain function and contribute to neurological diseases such as autism spectrum disorder and Parkinson's disease.[9]

Brain metabolism and neurological health:

The brain is a highly metabolically active organ, consuming approximately 20% of the body's total energy despite constituting only about 2% of its mass. This energy is essential for maintaining neuronal function, including synaptic transmission, ion gradients, and other cellular processes. Glucose is the brain's primary energy source under normal

physiological conditions. It undergoes glycolysis in the cytoplasm to produce pyruvate, which enters the mitochondria for oxidative phosphorylation, generating adenosine triphosphate (ATP), the energy currency required for neuronal activity.[10] Any disruption in these pathways can severely impact brain function, leading to cognitive decline and other neurological deficits.

In addition to glucose metabolism, the brain also relies on alternative energy substrates, particularly during periods of metabolic stress. Ketone bodies, derived from fatty acids, serve as an energy source during fasting or ketogenic diets. These molecules bypass the glycolytic pathway and directly enter the citric acid cycle in neurons, providing a neuroprotective effect by reducing oxidative stress and promoting mitochondrial efficiency (Newman & Verdin, 2014). Dysregulation in the metabolism of such alternative substrates has been implicated in conditions such as Alzheimer's disease, where glucose hypometabolism is a hallmark.[11]

Metabolites also play a critical role in neurotransmitter synthesis, which is essential for communication between neurons. For instance, the neurotransmitters glutamate and gamma-aminobutyric acid (GABA) are synthesized from intermediates of the tricarboxylic acid (TCA) cycle. The balance between excitatory (glutamate) and inhibitory (GABA) signaling is tightly regulated, and any disruption can result in pathological conditions such as epilepsy or schizophrenia.[12] Additionally, acetyl-CoA, a key metabolite, is used in the production of acetylcholine, a neurotransmitter vital for learning and memory, and its dysregulation has been linked to Alzheimer's disease.[13]

Oxidative metabolism in the brain also generates reactive oxygen species (ROS) as byproducts, necessitating robust antioxidant systems to maintain redox balance. Metabolites such as glutathione and ascorbate (vitamin C) act as primary antioxidants, neutralizing ROS and preventing oxidative damage. When the antioxidant defense is compromised, oxidative stress ensues, contributing to neurodegeneration and diseases such as Parkinson's disease and amyotrophic lateral sclerosis.[14]

The brain's metabolic requirements and the roles of metabolites extend beyond energy and signaling. Lipid metabolism is crucial for maintaining the structure and function of neuronal membranes. For example, myelin, the lipid-rich sheath insulating neurons, depends on proper lipid metabolism, and its disruption is associated with multiple sclerosis (Han *et al.*, 2018). Similarly, cholesterol, another key metabolite, is indispensable for synapse formation and neuronal repair, with dysregulation contributing to neurodegenerative conditions.[15]




Figure 1: Flowchart depicting the mechanism of brain metabolism and neurological health

Dysregulation of Metabolites in Neurological Diseases:

Dysregulation of metabolites is a hallmark of many neurological diseases, reflecting disruptions in the brain's tightly regulated metabolic pathways. These imbalances often impair neuronal function, leading to the onset and progression of various disorders. In Alzheimer's disease (AD), for instance, glucose hypometabolism is a well-documented phenomenon. The reduced ability of neurons to metabolize glucose leads to energy deficits, promoting amyloid-beta deposition and tau hyperphosphorylation, which are central to AD pathology.[16] Additionally, ketone bodies, which can serve as alternative energy substrates, are often insufficiently utilized in the AD brain, exacerbating metabolic deficiencies.[17]

Another example of metabolite dysregulation involves neurotransmitter metabolites. In Parkinson's disease (PD), the depletion of dopamine, a critical neurotransmitter

derived from the amino acid tyrosine, is a defining feature. This deficiency arises due to the degeneration of dopaminergic neurons in the substantia nigra, impairing motor control and leading to hallmark symptoms such as tremors and rigidity. Furthermore, the accumulation of dopamine metabolites, such as 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), has been linked to oxidative stress and neurotoxicity, contributing to further neuronal damage.[18] Glutamate, the primary excitatory neurotransmitter in the brain, also demonstrates significant dysregulation in neurological diseases. Elevated glutamate levels lead to excitotoxicity, a process that damages neurons due to overactivation of glutamate receptors. Excitotoxicity is implicated in acute conditions such as stroke and traumatic brain injury and chronic disorders like amyotrophic lateral sclerosis (ALS) and Huntington's disease.[19] The dysregulation of glutamate metabolism results in excessive calcium influx, mitochondrial dysfunction, and eventual cell death, highlighting the critical need to maintain glutamate homeostasis.

Oxidative stress, characterized by the excessive generation of reactive oxygen species (ROS) and insufficient antioxidant defenses, is another major contributor to metabolite dysregulation in neurological diseases. In multiple sclerosis (MS), lipid peroxidation products such as malondialdehyde and 4-hydroxynonenal accumulate, leading to damage of the myelin sheath and axons. These oxidative stress-related metabolites exacerbate neuroinflammation and neuronal injury, further driving disease progression.[20] Similarly, in ALS, imbalances in glutathione, a key antioxidant metabolite, have been associated with increased oxidative damage and motor neuron death.[21] Metabolite dysregulation is also evident in psychiatric disorders. In depression, the kynurenine pathway, which metabolizes tryptophan, is often altered. This dysregulation leads to an imbalance between neuroprotective kynurenic acid and neurotoxic quinolinic acid, contributing to inflammation and neuronal dysfunction. Such alterations in tryptophan metabolism have also been observed in schizophrenia, highlighting a shared metabolic vulnerability in psychiatric conditions.[22]




Figure 2: Flowchart depicting the mechanism of Dysregulation of Metabolites in Neurological Diseases

Oxidative Stress and Reactive Metabolites

Oxidative stress arises when the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) exceeds the capacity of the body's antioxidant defense systems. In the brain, which is highly susceptible to oxidative damage due to its high oxygen consumption, abundance of polyunsaturated fatty acids, and relatively low antioxidant capacity, oxidative stress plays a critical role in the pathogenesis of numerous neurological diseases.[23] ROS, such as superoxide anion and hydroxyl radicals, and RNS, such as nitric oxide, are by products of normal cellular metabolism, particularly oxidative phosphorylation in mitochondria. However, their overproduction or insufficient neutralization leads to damage to lipids, proteins, and DNA, which can disrupt neuronal function and viability.[24]

In neurodegenerative diseases like Alzheimer's disease (AD), oxidative stress is a significant contributor to disease progression. The accumulation of amyloid-beta plaques and tau tangles promotes mitochondrial dysfunction, resulting in excessive ROS generation. This oxidative environment damages cellular components and exacerbates neuronal loss. Additionally, oxidative modification of metabolites such as glucose

and lipids generates advanced glycation end products (AGEs) and lipid peroxidation by products like 4-hydroxynonenal (HNE), which further drive neurotoxicity and inflammation in AD.[25]

Parkinson's disease (PD) also involves substantial oxidative stress, particularly due to the metabolism of dopamine. Dopamine undergoes oxidative deamination by monoamine oxidase to produce hydrogen peroxide and other ROS. These reactive metabolites contribute to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of PD. Furthermore, the excessive accumulation of iron in these neurons catalyzes Fenton reactions, amplifying ROS production and neuronal damage.[26]

In amyotrophic lateral sclerosis (ALS), mutations in the antioxidant enzyme superoxide dismutase 1 (SOD1) impair its ability to detoxify superoxide radicals, leading to increased oxidative stress and motor neuron degeneration. Reactive metabolites generated during lipid peroxidation, such as malondialdehyde (MDA) and HNE, have been detected at elevated levels in ALS patients, underscoring the role of oxidative damage in disease progression.[27]

Multiple sclerosis (MS), a demyelinating disease, also involves oxidative stress and reactive metabolites. ROS and RNS produced during neuroinflammatory responses damage oligodendrocytes and myelin, exacerbating axonal injury. Lipid peroxidation products and nitric oxide metabolites are elevated in MS lesions, indicating their contribution to the disease's pathology. The imbalance between ROS production and antioxidant defenses, such as reduced glutathione levels, further amplifies oxidative damage in MS.[28] Antioxidant systems, including glutathione, catalase, and superoxide dismutase, play critical roles in mitigating oxidative stress by scavenging ROS and maintaining redox homeostasis. However, their dysfunction or depletion is a common feature of neurological diseases, making oxidative stress a viable therapeutic target. Strategies aimed at enhancing antioxidant defenses or reducing ROS production, such as the use of N-acetylcysteine or coenzyme Q10, are being explored for their potential to alleviate oxidative damage and slow disease progression.[29]




Figure 3: Flowchart depicting the mechanism of Oxidative Stress and Reactive Metabolites

Role of Gut-Brain Axis in Metabolic Regulation:

The gut-brain axis (GBA) is a complex, bidirectional communication network connecting the central nervous system (CNS) and the gastrointestinal (GI) tract, which plays an integral role in metabolic regulation. This system operates through neural, hormonal, and immune pathways, enabling the brain to regulate gut functions and vice versa. The gut microbiota, a key player in this axis, significantly impacts metabolic processes by producing metabolites and signaling molecules.[30]

One of the most studied metabolites in the GBA is short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, which are products of dietary fiber fermentation by gut microbiota. These SCFAs influence energy balance, glucose homeostasis, and brain function by interacting with receptors such as G-protein-coupled receptors (GPCRs) in both the gut and brain. They also modulate the release of neurotransmitters like serotonin and GABA, further linking gut microbial activity to central metabolic regulation.[31] The vagus nerve is a vital neural pathway in the GBA, transmitting information about nutrient availability and gut health to the brain. Hormonal signals like ghrelin, produced in the stomach, and leptin, secreted by adipose tissue, interact with the hypothalamus to regulate appetite and energy expenditure. Ghrelin stimulates hunger, whereas leptin

promotes satiety, creating a balance essential for maintaining metabolic homeostasis.[32] The hypothalamus serves as the central regulator of signals from the GBA. Incretin hormones, such as glucagon like peptide-1 (GLP-1) and peptide YY (PYY), are released by enteroendocrine cells in the gut in response to food intake. These hormones influence hypothalamic neurons to suppress appetite and enhance insulin sensitivity, demonstrating the importance of the GBA in glucose metabolism and energy balance.[33]

Dysfunction of the GBA is increasingly recognized in metabolic disorders such as obesity and diabetes. Gut dysbiosis, an imbalance in the gut microbiota, is associated with increased gut permeability and the translocation of lipopolysaccharides (LPS) into the bloodstream. This process triggers systemic inflammation, disrupting insulin signaling and contributing to metabolic syndrome.[34] Chronic stress also impacts the GBA, influencing gut motility, barrier integrity, and microbiota composition. Stress hormones like cortisol can alter the gut environment, leading to dysregulation of metabolic processes and increased susceptibility to metabolic disorders.[35] Therapeutic strategies targeting the GBA, such as probiotics, prebiotics, and dietary interventions, have shown promise in restoring gut microbiota balance and improving metabolic outcomes. These approaches aim to modulate gut-derived signals to positively influence brain and systemic metabolism, highlighting the therapeutic potential of the GBA.[36]




Figure 4: Mechanism of Role of Gut-Brain Axis in Metabolic Regulation

Biomarkers in Neurological Diseases:

Biomarkers serve as vital tools for understanding neurological disorders, aiding in diagnosis, monitoring disease progression, and evaluating treatment response. They are derived from a range of sources, including cerebrospinal fluid (CSF), blood, imaging modalities, and genetic analysis, offering valuable insights into the underlying pathophysiology of various conditions.[37]

In Alzheimer's disease (AD), CSF biomarkers such as amyloid-beta (Aβ42) and tau proteins are widely used. Reduced Aβ42 levels indicate amyloid plaque formation, while elevated total tau (t-tau) and phosphorylated tau (p-tau) levels reflect neurodegeneration and tau pathology. These markers, combined with imaging techniques like amyloid PET, improve the accuracy of early diagnosis and provide insights into disease progression.[38]

For Parkinson's disease (PD), alpha-synuclein, a protein involved in the formation of Lewy bodies, is a key biomarker. Misfolded alpha-synuclein can be detected in CSF and peripheral tissues, offering diagnostic value. Dopamine transporter imaging further assesses the integrity of dopaminergic neurons, enhancing diagnostic specificity in PD.[39]

In multiple sclerosis (MS), biomarkers such as neurofilament light chain (NfL) in CSF and blood serve as indicators of neuronal damage. NfL levels correlate with disease activity and progression, while the presence of oligoclonal bands (OCBs) in CSF remains a diagnostic hallmark of MS, reflecting localized immune activity in the central nervous system.[40]

Amyotrophic lateral sclerosis (ALS) research has identified neurofilament proteins, including NfL and phosphorylated neurofilament heavy chain (pNfH), as potential biomarkers. Elevated levels of these proteins in CSF and blood are associated with disease severity and prognosis, offering valuable tools for monitoring ALS progression.[41]

Neuropsychiatric disorders like depression and schizophrenia are linked to emerging biomarkers such as brain derived neurotrophic factor (BDNF), which is associated with neuronal growth and plasticity. Decreased BDNF levels in blood and imaging findings, including reduced connectivity in specific brain regions, may aid in stratifying patients and personalizing treatment approaches.[42]

Advanced technologies such as metabolomics, proteomics, and genomics have expanded biomarker discovery. For instance, metabolomic profiling identifies alterations in metabolites like amino acids and lipids, which reflect brain-specific changes. These novel biomarkers have the potential to provide earlier and more accurate diagnostic and prognostic insights.[43] Despite significant progress, challenges remain in implementing biomarkers for clinical use. Issues such as standardization of techniques, inter-individual variability, and accessibility must be addressed to fully realize the potential of biomarkers in neurological diseases. Nonetheless, they represent a promising frontier in personalized medicine for neurological care.[44]




Figure 5: Flowchart depicting the various mechanisms related to Biomarkers in Neurological Diseases

Therapeutic Implications of Metabolites:

Metabolites are central to understanding disease mechanisms and developing therapeutic strategies. Advances in metabolomics have paved the way for identifying key metabolites that can be targeted to restore homeostasis and alleviate disease burden. These therapeutic applications include using metabolites as direct drug targets and leveraging them in precision medicine approaches.[45] In neurological disorders, modulation of neurotransmitter-related metabolites has shown significant clinical impact. For example, in Parkinson's disease (PD), levodopa replenishes dopamine levels, mitigating motor symptoms. Furthermore, inhibitors of monoamine oxidase B (MAO-B), which slow dopamine breakdown, are also commonly used to enhance therapeutic effects.[46] Targeting oxidative stress and reactive oxygen species (ROS) through metabolites is another therapeutic avenue. In amyotrophic lateral sclerosis (ALS), edaravone, a free radical scavenger, has been approved for its ability to reduce oxidative damage. This highlights how targeting metabolic pathways involved in redox homeostasis can improve disease outcomes.[47]

The gut brain axis has garnered significant attention for its role in metabolic regulation and its therapeutic potential. Microbial metabolites such as short-chain fatty acids (SCFAs) influence central nervous system (CNS) function and immune responses. Probiotic and dietary interventions aim to modify gut microbiota composition to optimize metabolite production, showing promise in managing neurological disorders like depression and autism.[48] Cancer therapy also exploits metabolic dysregulation. Metabolic reprogramming in cancer cells, such as reliance on glycolysis (Warburg effect), has led to the development of therapies targeting these pathways. For example, inhibitors of hexokinase 2, an enzyme crucial for glycolysis, are being explored to disrupt cancer metabolism.[49] In diabetes management, therapies targeting metabolic pathways are well established. Drugs like metformin, which reduces hepatic glucose production, and GLP-1 receptor agonists, which enhance insulin secretion and improve glucose metabolism, demonstrate the success of metabolite-focused approaches. Gene-editing technologies, including CRISPR-Cas9, offer exciting opportunities to correct metabolic enzyme deficiencies. For instance, CRISPR-mediated editing of genes like G6PC in glycogen storage disease has shown potential for restoring metabolic balance.[50] In inflammatory and immune related disorders, modulating metabolite pathways holds therapeutic promise. Targeting the kynurenine pathway, which regulates immune tolerance, has shown potential in cancer immunotherapy. IDO inhibitors, which reduce the production of immunosuppressive metabolites, are undergoing clinical trials.[51]

Despite these advances, challenges persist, including variability in individual metabolic profiles and the need for standardized therapeutic approaches. Nonetheless, metabolite targeted therapies are reshaping the landscape of personalized medicine, offering hope for improved disease management.[52]




Figure 6: Flowchart depicting the various Therapeutic Implications of Metabolites

Challenges and Future Directions in Metabolite Research:

The promise of metabolite research lies in its potential to provide new insights into disease mechanisms and therapeutic strategies. However, significant challenges remain, particularly regarding the complexity of metabolomic data and its translation into clinical applications. The development of advanced technologies, coupled with interdisciplinary approaches, holds great promise for overcoming these challenges and advancing the field of metabolomics.[53] One of the major hurdles in metabolomics is the vast complexity of metabolic networks. Metabolites are interconnected in intricate ways, influenced by genetic, environmental, and lifestyle factors. To effectively analyze metabolomic data, sophisticated computational techniques, such as artificial intelligence (AI) and machine learning, are necessary to identify and interpret patterns that are meaningful for disease diagnosis and therapy.[54] Furthermore, there is a need for standardization in metabolomic data collection and analysis to ensure that results are reproducible across different studies and laboratories.[55]

The dynamic nature of metabolites is another significant challenge. Unlike genes or proteins, metabolite levels fluctuate constantly due to external and internal factors such as diet, circadian rhythms, or disease progression. Real-time tracking and accurate quantification of metabolites in biological samples remain technically demanding. Emerging technologies, such as non-invasive biosensors and wearable devices, offer potential solutions to track metabolite levels over time, but these are still in early stages of development[56]. Despite the promise of metabolite-based biomarkers, their clinical application faces challenges related to variability and the reproducibility of results. Factors such as genetic differences, environmental exposures, and disease heterogeneity mean that the same metabolite can behave differently in different individuals. Therefore, large-scale studies to identify universally applicable biomarkers and establish clinical reference ranges for metabolites are crucial[57]. Additionally, integrating metabolomics into routine clinical practice requires overcoming logistical barriers related to infrastructure and data management[58].

The role of the gut microbiome in metabolite production is another emerging area of interest. The gut microbiota significantly influences the synthesis of metabolites that impact both metabolic and immune processes in the host. However, understanding the complexities of these interactions requires combining microbiome data with metabolomics, which remains a major challenge due to the inter-individual variability in microbiota composition and metabolite production[59]. Looking forward, the integration of multi-omics approaches (such as genomics, transcriptomics, proteomics, and metabolomics) will provide a more holistic understanding of human health and disease. This integrative approach will enhance our ability to identify novel disease mechanisms and therapeutic targets[60]. The use of AI in metabolomic data analysis will further accelerate discoveries, enabling the development of precision medicine strategies tailored to individual metabolic profiles[61]. Additionally, personalized medicine is expected to be a major future direction for metabolite research. By understanding individual variations in metabolic pathways, personalized therapeutic interventions can be designed to optimize treatment effectiveness and minimize side effects. For example, metabolic profiling could be used to guide the choice of diet, drug therapy, or lifestyle interventions in managing chronic diseases such as diabetes, cardiovascular disease, and neurodegenerative conditions.[62]

Finally, ethical considerations surrounding metabolite-based diagnostics and therapies must be addressed. Ensuring that these

advancements are accessible and equitable, particularly in low-resource settings, is essential for the widespread adoption of metabolomics in clinical practice. Efforts should be made to ensure data privacy and prevent the misuse of personal health information.[63] Although metabolite research faces several challenges, continued technological innovations and collaborations between various scientific disciplines hold great potential. The future of metabolomics is bright, with the possibility of revolutionizing disease diagnosis, prognosis, and therapy in personalized and precision medicine.[53]

CONCLUSION

Metabolites play a crucial role in the pathophysiology of neurological diseases, providing insights into disease mechanisms and potential therapeutic approaches. As small molecules involved in metabolism, metabolites are essential for maintaining cellular function and metabolic balance, and their dysregulation can contribute to disorders like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Recent advances in metabolomics have enabled the identification of biomarkers that could facilitate early diagnosis, which is critical for timely intervention in neurodegenerative diseases where clinical symptoms often emerge late. Brain metabolism is integral to neurological health, and disruptions in metabolic pathways such as mitochondrial dysfunction or altered neurotransmitter metabolism are central to the progression of neurological diseases. For example, mitochondrial impairments in Alzheimer's disease and dopamine dysregulation in Parkinson's disease have become key targets for therapeutic interventions. Identifying metabolites involved in these pathways can pave the way for new treatments aimed at restoring metabolic balance. Additionally, the gut brain axis has emerged as a significant player in brain health. Gut derived metabolites, such as short chain fatty acids, influence brain function and immune responses, offering novel therapeutic avenues for conditions like depression and autism spectrum disorders. The exploration of microbiome based interventions is a promising area in the treatment of neurological diseases. Despite these advancements, challenges remain. The complexity of metabolomic data, influenced by numerous external factors, makes it difficult to isolate specific disease related metabolites. Individual metabolic variability further complicates the identification of universal biomarkers. However, the integration of multi-omics approaches and the application of artificial intelligence hold promise in overcoming these challenges and facilitating the clinical translation of metabolomic findings.

In conclusion, metabolite research offers great potential for understanding and treating neurological diseases. While challenges in data analysis and clinical application persist, the future of metabolomics in neurological health is promising, with the potential to revolutionize early diagnosis, personalized treatment strategies, and targeted therapies. Ongoing advancements will likely reshape the landscape of neurological disease management.

Conflict of Interest: Nil

REFERENCES

1. Nicholson J.K., Lindon J.C., Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica Fate Foreign Compd Biol Syst. 1999 Nov; 29(11): 1181–9.
2. Patti G.J., Yanes O., Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012 Apr; 13(4): 263–9.
3. Johnson C.H., Ivanisevic J., Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016 Jul; 17(7): 451–9.
4. Kaddurah-Daouk R., Krishnan K.R.R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2009 Jan; 34(1): 173–86.
5. Butterfield D.A., Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019 Mar; 20(3): 148–60.
6. Zheng C., Shao W., Chen X., Zhang B., Wang G., Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2022 Jan; 114: 252–60.
7. Lewén A., Matz P., Chan P.H. Free radical pathways in CNS injury. J Neurotrauma. 2000 Oct; 17(10): 871–90.

8. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri AMA. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007 Feb; 81(2): 89–131.

9. Morais L.H., Schreiber H.L., Mazmanian S.K. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021 Apr; 19(4): 241–55.

10. Harris J.J., Jolivet R., Attwell D. Synaptic energy use and supply. Neuron. 2012 Sep 6; 75(5): 762–77.

11. Cunnane S.C., Trushina E., Morland C., Prigione A., Casadesus G., Andrews Z.B., *et al.* Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020 Sep; 19(9): 609–33.

12. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., *et al.* So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013 Sep 12; 11: 200.

13. Ferreira-Vieira T.H., Guimaraes I.M., Silva F.R., Ribeiro F.M. Alzheimer's disease: Targeting the Cholinergic System. Curr Neuropharmacol. 2016; 14(1): 101–15.

14. Chen Y., Yao H., Zhang N., Wu J., Gao S., Guo J., *et al.* Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage. J Proteome Res. 2021 Jul 2; 20(7): 3463–74.

15. Martín M.G., Pfrieger F., Dotti C.G. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep. 2014 Oct; 15(10):1 036–52.

16. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013 Sep; 108: 21–43.

17. Kapogiannis D., Avgerinos K.I. Brain glucose and ketone utilization in brain aging and neurodegenerative diseases. Int Rev Neurobiol. 2020; 154: 79–110.

18. Sian-Hülsmann J., Mandel S., Youdim MBH, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem. 2011 Sep; 118(6): 939–57.

19. Dong X. xia, Wang Y., Qin Z. hong. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009 Apr; 30(4): 379–87.

20. Lassmann H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J Neural Transm Vienna Austria 1996. 2011 May; 118(5): 747–52.

21. Baillet A., Chanteperdrix V., Trocmé C., Casez P., Garrel C., Besson G. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res. 2010 Oct; 35(10): 1530–7.

22. Stone T.W., Darlington L.G. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol. 2013 Jul; 169(6): 1211–27.

23. Angelova P.R., Abramov A.Y. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. FEBS Lett. 2018 Mar; 592(5): 692–702.

24. Gandhi S., Abramov A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev. 2012;2012:428010.

25. Praticò D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci. 2008 Dec;29(12):609–15.

26. Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis VR. Oxidative stress and Parkinson's disease. Front Neuroanat. 2015; 9: 91.

27. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol. 2000 Mar; 247 Suppl 1: I1-6.

28. Fischer M.T., Sharma R., Lim J.L., Haider L., Frischer J.M., Drexhage J., *et al.* NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain J Neurol. 2012 Mar; 135(Pt 3): 886–99.

29. Mancuso M., Orsucci D.., Volpi L., Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010 Jan;11(1):111–21.

30. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015; 28(2): 203–9.

31. Blaut M., Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr. 2007 Mar; 137(3 Suppl 2): 751S-5S.

32. Date Y., Kojima M., Hosoda H., Sawaguchi A, Mondal M.S., Suganuma T., *et al.* Ghrelin, a novel growth hormone-releasing acylated

peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000 Nov; 141(11): 4255–61.

33. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct; 87(4): 1409–39.

34. Turnbaugh P.J., Ley R.E., Mahowald MA, Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 Dec; 444(7122): 1027–31.

35. Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X.N., *et al.* Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004 Jul 1; 558(Pt 1): 263–75.

36. Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., *et al.* Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013 Sep 6; 341(6150): 1241214.

37. Del Prete E., Beatino M.F., Campese N., Giampietri L., Siciliano G., Ceravolo R., *et al*. Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. J Pers Med. 2020 Nov 11; 10(4): 221.

38. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J, *et al.* Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010 Jul; 9(7): 560–74.

39. Lashuel H.A., Overk C.R., Oueslati A., Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013 Jan; 14(1): 38–48.

40. Disanto G., Barro C., Benkert P., Naegelin Y., Schädelin S., Giardiello A., *et al.* Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun; 81(6): 857–70.

41. Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009 Jan; 8(1): 94–109.

42. Molendijk ML, Spinhoven P., Polak M., Bus B a. A, Penninx BWJH, Elzinga B.M. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014 Jul; 19(7): 791–800.

43. Hassan-Smith G., Wallace G.R., Douglas MR, Sinclair A.J. The role of metabolomics in neurological disease. J Neuroimmunol. 2012 Jul 15; 248(1–2): 48–52.

44. Cummings J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement J Alzheimers Assoc. 2011 May; 7(3): e13-44.

45. Fiehn O. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling. Curr Protoc Mol Biol. 2016 Apr 1; 114: 30.4.1-30.4.32.

46. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009 May 26; 72(21 Suppl 4): S1-136.

47. Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019 Mar; 39(2): 733–48.

48. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, *et al*. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019 Oct 1; 99(4): 1877–2013.

49. Verma V., Kumar A., Partap M., Thakur M., Bhargava B. CRISPR-Cas: A robust technology for enhancing consumer-preferred commercial traits in crops. Front Plant Sci. 2023 Feb 7; 14: 1122940.

50. Sharma G., Sharma A.R., Bhattacharya M., Lee S.S., Chakraborty C. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Mol Ther. 2021 Feb 3; 29(2): 571–86.

51. Munn D.H., Mellor A.L. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016 Mar; 37(3): 193–207.

52. Roberts L.D., Souza A.L., Gerszten RE, Clish CB. Targeted Metabolomics. Curr Protoc Mol Biol. 2012; 98(1): 30.2.1-30.2.24.

53. Litman T. Personalized medicine concepts, technologies, and applications in inflammatory skin diseases. Apmis. 2019 May 24; 127(5): 386.

54. Schmidt D.R., Patel R., Kirsch D.G., Lewis C.A., Vander Heiden M.G., Locasale J.W. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin. 2021; 71(4): 333–58.

55. Vermeersch K.A., Styczynski M.P. Applications of metabolomics in cancer research. J Carcinog. 2013 Jun 18; 12:9.

56. Vaghasiya J.V., Mayorga-Martinez C.C., Pumera M. Wearable sensors for telehealth based on emerging materials and nanoarchitectonics. Npj Flex Electron. 2023 Jun

2; 7(1): 1–14.

57. Long N.P., Nghi T.D., Kang Y.P., Anh N.H., Kim H.M., Park S.K., *et al.* Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine. Metabolites. 2020 Jan 29; 10(2): 51.

58. Pinu F.R., Goldansaz S.A., Jaine J. Translational Metabolomics: Current Challenges and Future Opportunities. Metabolites. 2019 Jun 6;9(6):108.

59. Khalil M., Di Ciaula A., Mahdi L., Jaber N., Di Palo D.M., Graziani A., *et al.* Unraveling the Role of the Human Gut Microbiome in Health and Diseases. Microorganisms. 2024 Nov 15; 12(11): 2333.

60. Zhan C., Tang T., Wu E., Zhang Y., He M., Wu R., *et al.* From multi-omics approaches to personalized medicine in myocardial infarction. Front Cardiovasc Med. 2023 Oct 30; 10: 1250340.

61. Gao F., Huang K., Xing Y. Artificial Intelligence in Omics. Genomics Proteomics Bioinformatics. 2022 Oct; 20(5): 811–3.

62. Chowdhury S., Faheem S.M., Nawaz SS, Siddiqui K. The role of metabolomics in personalized medicine for diabetes. Pers Med. 2021 Sep; 18(5): 501–8.

63. Astudillo A.A., Mayrovitz H.N. The Gut Microbiome and Cardiovascular Disease. Cureus. 13(4): e14519.